Tuftsin

Tuftsin (L-threonyl-L-lysyl-L-prolyl-L-arginine) is an endogenous tetrapeptide corresponding to residues 289 through 292 of the CH2 domain of the immunoglobulin G (IgG) heavy chain. First identified in 1970 by Victor A. Najjar and Keisuke Nishioka at the Tufts University School of Medicine during investigations of phagocytosis by polymorphonuclear granulocytes, the peptide derives its name from its institutional origin and has since become the prototype endogenous immunostimulatory peptide. Tuftsin is not synthesized de novo but is liberated from a larger IgG-associated polypeptide termed leukokinin through the sequential action of two proteases: tuftsin-endocarboxypeptidase, a splenic enzyme that cleaves the C-terminal bond of the tetrapeptide within the intact immunoglobulin, and leukokinase, a serine protease on the outer membrane of phagocytic cells that releases the active N-terminal tetrapeptide from the partially processed fragment. This two-step enzymatic liberation places the spleen as an obligate organ in tuftsin physiology and accounts for the well-documented tuftsin deficiency, impaired phagocytic function, and increased susceptibility to overwhelming bacterial infection observed following splenectomy.

The molecular pharmacology of tuftsin centers on its binding to neuropilin-1 (NRP1), a single-pass transmembrane glycoprotein that also serves as a co-receptor for vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta). Tuftsin binds the b1 domain of neuropilin-1 through a motif similar to the C-terminal sequence encoded by exon 8 of VEGF165, and signals through TGF-beta receptor 1 (a co-receptor of NRP1) via the canonical Smad3 phosphorylation pathway, with concurrent reduction in Akt phosphorylation. At the cellular level, tuftsin binding stimulates phagocytosis, pinocytosis, chemotaxis, respiratory burst (superoxide anion and hydrogen peroxide generation), antigen presentation, and tumoricidal activity in monocytes, macrophages, neutrophils, microglia, and Kupffer cells. Intracellular calcium serves as a critical second messenger in tuftsin-mediated phagocyte activation. In neuroinflammatory models, tuftsin promotes an anti-inflammatory M2 microglial phenotype shift, suppresses pro-inflammatory Th1 responses, upregulates Th2 responses, and expands regulatory T cell populations.

Pharmacokinetically, tuftsin is an extremely labile peptide in vivo, with a plasma half-life of approximately 16 minutes owing to rapid degradation by serum aminopeptidases and carboxypeptidases. Oral bioavailability is negligible because of gastric peptidase destruction. The rapid enzymatic clearance has been the principal barrier to clinical development. Initial clinical studies conducted at the Weizmann Institute of Science demonstrated that tuftsin is nontoxic in humans when administered intravenously at doses up to 5 mg per injection in patients with advanced malignancy; a Phase II study in 25 patients with various advanced cancers reported leucocytosis and increased natural killer activity with two partial responses among 16 evaluable patients, confirming biological activity but insufficient monotherapy efficacy.

The most significant translational legacy of tuftsin is the development of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic heptapeptide analog in which the tuftsin sequence is extended at the C-terminus with a Pro-Gly-Pro tripeptide motif that confers resistance to enzymatic degradation and facilitates blood-brain barrier penetration. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia as a nasal spray for generalized anxiety disorder and neurasthenia. Selank exhibits pronounced anxiolytic, nootropic, and immunomodulatory activity through mechanisms including allosteric modulation of GABA-A receptors and modulation of monoamine neurotransmitter metabolism, and does so without the sedation, tolerance, or dependence associated with benzodiazepines.

Beyond Selank, tuftsin has been developed as a targeting ligand for liposomal and nanoparticle drug delivery systems. Palmitoyl tuftsin grafted onto liposome surfaces enables selective binding to phagocytic cells and has demonstrated augmented antitumor efficacy of encapsulated cytotoxic agents (etoposide, doxorubicin, curcumin) against fibrosarcoma and Ehrlich ascites carcinoma in murine models. Tuftsin-bearing liposomes have also been used to deliver antimicrobial agents to macrophage-resident intracellular pathogens including Leishmania and Plasmodium species.

This monograph reviews the chemistry, enzymatic biogenesis, and structural biology of tuftsin; the neuropilin-1 receptor pharmacology and downstream signaling; the pharmacokinetic constraints and stabilization strategies; the preclinical pharmacology across immunostimulatory, anti-inflammatory, antitumor, and anti-infective applications; the clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five immunostimulatory peptide candidates (Selank, thymosin alpha-1, muramyl dipeptide, GM-CSF, and thymopentin) against tuftsin on five competency standards.